Search research articles
Contact Us
Filters
Showing results (201-210 of 305) with videos related to
Page
of 31
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
Kurt A Jaeckle, Kenneth R Hess, W K Alfred Yung, et al.
Neuro-Oncology Advances
|
December 23, 2024
Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma
Crismita Dmello, Andrew Brenner, David Piccioni, et al.
Neuro-Oncology Advances
|
October 13, 2022
A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma
Priya Kumthekar, Sean Aaron Grimm, Roxanne T Aleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Neuro-Oncology
|
April 12, 2020
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic
Nimish A Mohile, Jaishri O Blakeley, Na Tosha N Gatson, et al.
Neuro-Oncology
|
October 16, 2025
Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas
David Schiff, Xiaobu Ye, Jing Li, et al.
The Oncologist
|
December 15, 2010
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
James J Vredenburgh, Timothy Cloughesy, Meghna Samant, et al.
Neuro-Oncology
|
November 19, 2010
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
Michael Prados, Timothy Cloughesy, Meghna Samant, et al.
Blood
|
October 27, 2007
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Nancy D Doolittle, Lauren E Abrey, Tamara N Shenkier, et al.
Page
of 31
Search research articles
Search
Showing results (201-210 of 305) with videos related to
Sort By:
Page
of 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 14, 2003
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
Kurt A Jaeckle, Kenneth R Hess, W K Alfred Yung, et al.
Neuro-Oncology Advances
|
December 23, 2024
Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma
Crismita Dmello, Andrew Brenner, David Piccioni, et al.
Neuro-Oncology Advances
|
October 13, 2022
A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma
Priya Kumthekar, Sean Aaron Grimm, Roxanne T Aleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2009
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
Henry S Friedman, Michael D Prados, Patrick Y Wen, et al.
Neuro-Oncology
|
April 12, 2020
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic
Nimish A Mohile, Jaishri O Blakeley, Na Tosha N Gatson, et al.
Neuro-Oncology
|
October 16, 2025
Phase I/II and Window-of-Opportunity Study of Pamiparib and Metronomic Temozolomide for Recurrent IDH Mutant Gliomas
David Schiff, Xiaobu Ye, Jing Li, et al.
The Oncologist
|
December 15, 2010
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
James J Vredenburgh, Timothy Cloughesy, Meghna Samant, et al.
Neuro-Oncology
|
November 19, 2010
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
Michael Prados, Timothy Cloughesy, Meghna Samant, et al.
Blood
|
October 27, 2007
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Nancy D Doolittle, Lauren E Abrey, Tamara N Shenkier, et al.
Page
of 31